GI
FULC icon

GAMMA Investing’s Fulcrum Therapeutics FULC Stock Holding History

GAMMA Investing’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25
Closed -$283 – 4165
2025
Q4 		$283 Buy
+25
New +$254 ﹤0.01% 3972
2024
Q4 		– Sell
-198
Closed -$707 – 3796
2024
Q3 		$707 Buy
+198
New +$1.47K ﹤0.01% 3337
2024
Q2 		– Sell
-45
Closed -$425 – 3480
2024
Q1 		$425 Buy
+45
New +$402 ﹤0.01% 3129

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

GAMMA Investing's FULC Position: Q1 2026 in Review

GAMMA Investing sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 25 shares — an estimated $283 sold.

GAMMA Investing first reported a position in FULC in Q1 2024 and held it in 3 quarters. The position peaked at $707 in Q3 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • GAMMA Investing reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GAMMA Investing sold 25 Fulcrum Therapeutics shares in Q1 2026, an estimated $283.
  • GAMMA Investing first reported a position in Fulcrum Therapeutics in Q1 2024 and held it in 3 quarters.
  • GAMMA Investing's Fulcrum Therapeutics position peaked at $707 in Q3 2024.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on GAMMA Investing's 13F filing for Q1 2026, filed 6 Apr 2026.